All In Biotech

Drug Trial Radar · NCT02202564

Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Jul 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Oct 2006

Primary completion

Oct 2011

Study completion Aug 2013

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing YouAn Hospital
First posted
Jul 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HCC patients with tumors \>5 cm in diameter, regardless of involvement in the intrahepatic and extrahepatic portal branches participated in the study. Patients were randomized allocated in liver transplantation (LT) only group and LT plus ADV-TK therapy group. All patients received orthotopic liver transplantation; in the LT plus ADV-TK group, ADV-TK therapy was delivered to patients twice.

Conditions

  • Liver Cancer
  • Hepatocellular Carcinoma

Interventions

  • LTProcedure

    Orthotopic LT

  • ADV-TKDrug

  • ganciclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival rateTime frame: up to 3-year
  2. Recurrence-free survival rateTime frame: up to 3-year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.